Edgewise Therapeutics Inc EWTX Stock Analysis
- Nasdaq
- Stock
- Market open · no trades yet today
$38.80 up $1.27, 3.38% at close Nov 5
Last close · Previous close $37.53
- Market cap
- At the Nov 5 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.86Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$38.80up $1.27, 3.38%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$37.53Nov 4
- Volume1.08MNov 4 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.35MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $16.70 to $48.51; now $38.80
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
EWTX beat the S&P 500 in 5 of 6 periods.
| Period | EWTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | EWTX: down 3.7% S&P 500: down 5.4% | EWTX beat the S&P 500 by 1.7 percentage points Beat |
| 3M | EWTX: down 13.8% S&P 500: down 4.5% | EWTX trailed the S&P 500 by 9.3 percentage points Trailed |
| YTD | EWTX: up 56.4% S&P 500: up 8.3% | EWTX beat the S&P 500 by 48.1 percentage points Beat |
| 1Y | EWTX: up 123.4% S&P 500: up 9.3% | EWTX beat the S&P 500 by 114.1 percentage points Beat |
| Long term | ||
| 3Y | EWTX: up 475.7% S&P 500: up 74.8% +79.2% vs +20.5% a year | EWTX beat the S&P 500 by 400.9 percentage points Beat |
| 5Y | EWTX: up 95.0% S&P 500: up 67.3% +14.3% vs +10.8% a year | EWTX beat the S&P 500 by 27.7 percentage points Beat |
$10,000 invested in EWTX 5 years ago (Nov 5, 2021) would be worth about $19,497 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,730.
EWTX beat the S&P 500 in 5 of 6 periods.
| Period | EWTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | EWTX: down 3.7% S&P 500: down 5.4% | EWTX beat the S&P 500 by 1.7 percentage points Beat |
| 3M | EWTX: down 13.8% S&P 500: down 4.8% | EWTX trailed the S&P 500 by 9.0 percentage points Trailed |
| YTD | EWTX: up 56.4% S&P 500: up 7.5% | EWTX beat the S&P 500 by 48.9 percentage points Beat |
| 1Y | EWTX: up 123.4% S&P 500: up 8.2% | EWTX beat the S&P 500 by 115.2 percentage points Beat |
| Long term | ||
| 3Y | EWTX: up 475.7% S&P 500: up 68.6% +79.2% vs +19.0% a year | EWTX beat the S&P 500 by 407.1 percentage points Beat |
| 5Y | EWTX: up 95.0% S&P 500: up 56.4% +14.3% vs +9.4% a year | EWTX beat the S&P 500 by 38.6 percentage points Beat |
$10,000 invested in EWTX 5 years ago (Nov 5, 2021) would be worth about $19,497 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,645.
All-time high
$48.35
Closing high on . Now 19.8% below that record.
Split-adjusted daily closes since Mar 26, 2021.
Stock splits
EWTX hasn’t split since its price history begins in 2021.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$197.22M
- Diluted EPS
- −$1.86
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$34.13M | −$0.36 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$39.66M | −$0.42 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$40.80M | −$0.43 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$36.12M | −$0.34 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$40.67M | −$0.39 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$50.22M | −$0.48 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$49.01M | −$0.46 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$57.33M | −$0.53 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$42.81M | −$1.14 |
| FY22 (Dec 31, 2022) | $0.00 | −$67.64M | −$1.26 |
| FY23 (Dec 31, 2023) | $0.00 | −$100.16M | −$1.57 |
| FY24 (Dec 31, 2024) | $0.00 | −$133.81M | −$1.45 |
| FY25 (Dec 31, 2025) | $0.00 | −$167.80M | −$1.63 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$158.83MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$158.38MLast 12 months
- Capital spending$454.00KLast 12 months
Shareholder returns
- $20.89MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $460.71MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$3.59MAs of Jun 30, 2026
- Net cash$457.12MAs of Jun 30, 2026
- 16.24As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −39.0%Last 12 months
Over the last 12 months, Edgewise Therapeutics lost money: its net loss was 39.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −37.0%Last 12 months
Over the last 12 months, Edgewise Therapeutics’s net loss was 37.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Edgewise Therapeutics Inc
Edgewise Therapeutics Inc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
EWTX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
EWTX stock FAQ
What is EWTX stock’s price today?
Edgewise Therapeutics (EWTX) traded at $38.80 at the close on , up $1.27 (3.38%) from the previous close of $37.53. Over the past 52 weeks it has traded between $16.70 and $48.51.
If you invested $1,000 in EWTX 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in EWTX on would be worth about $1,950 at the close on , a total return of +95.0%. The same $1,000 would be worth $2,234 if invested one year ago. Past performance doesn’t predict future returns.
What is EWTX’s P/E ratio?
EWTX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.86).
What are EWTX’s earnings per share?
EWTX’s diluted earnings per share were −$1.86 over the four quarters to , compared with −$1.55 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.53 per share, against −$0.34 a year earlier (how EPS works).
Does EWTX pay a dividend?
Edgewise Therapeutics hasn’t paid a dividend in the last twelve months.
What is EWTX’s 52-week high and low?
Over the past 52 weeks EWTX has traded as low as $16.70 and as high as $48.51. At $38.80 at the close on , it is 20.0% below that high and 132.3% above the low.
What is EWTX’s all-time high?
EWTX’s highest closing price was $48.35 on , adjusted for stock splits. At $38.80 at the close on , it is 19.8% below that record.
Has EWTX stock ever split?
No. EWTX hasn’t split since its price history begins in 2021.
How has EWTX stock performed?
Including dividends and measured to the close on , EWTX has returned +56.4% so far this year and +123.4% over the past year, and +95.0% over five years (+14.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What sector and industry is Edgewise Therapeutics in?
Edgewise Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does EWTX trade on?
Edgewise Therapeutics trades on the Nasdaq under the ticker symbol EWTX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.